The role of Programmed cell death 1 ligand 1 (PD-L1) in CRC management is controversial: only a minority of CRC individuals (typically MSI ones) positively react to anti-PD-L1/PD-1 therapy [20]. This evidence concerns the gene CD274 and colorectal carcinoma.